{Reference Type}: Journal Article
{Title}: Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic Cancer.
{Author}: Marinova M;Khouri DA;Küppers J;Ramig O;Strunk HM;Breuers J;Fazaal J;Fuhrmann C;Coenen M;Möhring C;Zhou T;Zhou X;Anhalt T;Sadeghlar F;Thudium M;Conrad R;Feldmann G;Brossart P;Glowka TR;Kalff JC;Essler M;Strassburg CP;Ko YD;Schmidt-Wolf IGH;Gonzalez-Carmona M;
{Journal}: J Clin Med
{Volume}: 13
{Issue}: 13
{Year}: 2024 Jun 26
{Factor}: 4.964
{DOI}: 10.3390/jcm13133717
{Abstract}: <B>BACKGROUND: </B>Pancreatic adenocarcinoma (PaC) still has a dismal prognosis, and despite medical advances, a bleak 5-year survival rate of only 8%, largely due to late diagnosis and limited curative surgical options for most patients. Frontline palliative treatment shows some survival advantages. However, the high disease mortality is accompanied by high morbidity including cancer-related pain and additional symptoms, which strongly impair patients' quality of life (QOL). At present, there is no established strategy for local therapy for PaC primarily aiming to manage local tumor growth and alleviate associated symptoms, particularly pain. In recent years, non-invasive high-intensity focused ultrasound (HIFU) has shown promising results in reducing cancer pain and tumor mass, improving patients' QOL with few side effects.<BR><B>METHODS: </B>This is the first randomized controlled trial worldwide including 40 patients with inoperable pancreatic adenocarcinoma randomized into two groups: group A undergoing standard chemotherapy; and group B undergoing standard chemotherapy plus local HIFU treatment. This study aims to establish a robust evidence base by examining the feasibility, safety, and efficacy of US-guided HIFU in combination with standard palliative systemic therapy for unresectable PaC. Primary endpoint assessments will focus on parameters including safety issues (phase I), and local response rates (phase II).